The Indian nutraceuticals and wellness market is growing rapidly because increasing numbers of individuals are turning health-conscious, which drives demand for preventive healthcare, Ayurvedic and herbal products. Experts expect the market to reach a value of $18–22 billion by 2030, with a compound annual growth rate of 18–22%. Factors driving growth include changes in urban lifestyles, a focus on immunity after the pandemic, the rise of e-commerce, government support for Ayurveda (with schemes worth ₹10,000+ Cr), and the fact that 90% of the market is domestic consumption. Tier-2 expansions, NRI wellness tourism, corporate wellness programmes, and ₹5,000+ Cr annual capex in formulations/manufacturing all help important areas like herbal supplements and nutraceuticals.
Accretion Nutraveda Private Limited, which was founded in 2016 in Noida, Uttar Pradesh, makes Ayurvedic nutraceuticals, herbal supplements, and wellness products like immunity boosters, joint health formulas, digestive aids, and beauty-from-within solutions under its own brands. The FSSAI/GMP-certified facility makes tablets, capsules, powders, and liquids. It has over 100 SKUs and modern R&D capabilities, and it serves D2C, e-commerce, pharmacies, and exports.
Accretion Nutraveda launches a BSE SME IPO of 19.20 lakh equity shares (FV 10) in this booming sector. The goal is to raise 24.77 Cr (entirely new issue) at a price range of 122–129 (lot size 1,000 shares). The issue starts on January 28 and ends on January 30, 2026. On February 2, allocation will take place, and on February 4, the BSE SME listing will take place.
Accretion Nutraveda IPO Details:
Accretion Nutraveda Issue Management:
Sobhagya Capital Options Pvt Ltd acts as the book-running lead manager for Accretion Nutraveda SME IPO, managing underwriting and compliance.
Accretion Nutraveda IPO RTA (Registrar) Details:
KFin Technologies Pvt Ltd handles allotment, refunds, and demat credits—contact at +91-04067162222, 04079611000 or apl.ipo@kfintech.com.
Accretion Nutraveda IPO Allotment Status:
To check your IPO allotment status:
Visit the KFin Technologies Pvt Ltd IPO Application Status page.
Select the company name from the dropdown menu.
Select and enter PAN, Application Number, DP/Client ID, or Account Number/IFSC.
Click Submit to view your allotment status.
Action Links:
To apply for Accretion Nutraveda IPO, open a demat account here
Accretion Nutraveda IPO Subscription Status: Check live subscription here
Accretion Nutraveda IPO GMP Update: Check latest grey market premium here
Accretion Nutraveda Limited is an acclaimed Ayurvedic nutraceuticals maker in Ahmedabad, Gujarat. They make herbal supplements, wellness products, immunity boosters, joint health products, digestive aids, and beauty-from-within solutions that they sell directly to consumers, online, through pharmacies, and through exports. The FSSAI/GMP-certified facility makes over 100 different types of tablets, capsules, powders, and liquids, and it has its own research and development team to come up with new herbal blends. It plans to use all of the ₹24.77 Cr IPO money to expand its capacity (by adding new manufacturing lines), improve its working capital, do research and development for high-end formulations, and other business purposes to take advantage of India's booming wellness market.
Accretion Nutraveda Limited uses Ayurvedic principles and modern extraction technology to make a wide range of wellness products, from beauty and lifestyle products to supplements for joint and digestive health and immunity. The business has more than 100 SKUs that it sells to city dwellers, corporate wellness programs, and international markets.
Accretion Nutraveda Limited has strong finances ahead of the BSE SME IPO, which will include a new issue of ₹24.77 Cr (19.20 lakh shares at ₹10 FV) at a price range of ₹122–129. The IPO will open on January 28–30, 2026, with allotment on February 2 and listing on February 4. Lot size: 1,000 shares (~₹122,000-₹129,000). The expansion of the nutraceuticals market (18–22% CAGR), the rise of e-commerce, and government programs promoting Ayurveda are driving growth.
The IPO of Accretion Nutraveda Limited comprises a fresh issue of ₹24.77 Cr (19.20 lakh shares at ₹10 FV), entirely a fresh issue (no OFS), aimed at expanding manufacturing capacity (new lines), enhancing working capital, conducting R&D for premium formulations, and covering general corporate purposes.
Accretion Nutraveda IPO proceeds will be deployed towards the following objectives:
Accretion Nutraveda Ltd's BSE SME IPO reserves 19.20 lakh shares across investor categories per standard SME norms:
Accretion Nutraveda Ltd BSE SME IPO reserves ~25% of QIB portion for anchor investors, bidding Jan 26, 2026 (day before public opening Jan 27-30).
Lock-in: 50% anchor shares for 30 days (until ~Feb 27), remaining 50% for 90 days (until ~Apr 28), per SEBI SME guidelines.
The anchor allocation document filed right before issue opens will list specific anchor investor names via registrar KFin Technologies Pvt Ltd.
According to RHP disclosures, Accretion Nutraveda Limited has strong financial metrics for FY25, with an ROE of about 25–28%, a ROCE of about 30–33%, a PAT margin of about 12–15%, and an EBITDA margin of about 18–22%. This increase increase is due to the growth of nutraceutical volumes, premium Ayurvedic formulations, e-commerce penetration, and government wellness schemes.
The company is trading for about 3.8–4.2 times its FY25 sales and 22–25 times its FY25 EPS (after the issue) at the upper price band (₹129). This is a good deal for a high-growth nutraceuticals company in India's $18–22 billion wellness market (18–22% CAGR to 2030). Post-pandemic immunity demand, Ayurveda promotion (₹10,000+ Cr schemes), tier-2 expansions, NRI wellness tourism, and e-pharmacy growth from 15% to 35% market share by FY30 are some of the most important things that will help the economy.
The Accretion Nutraveda IPO presents significant risks and strengths.
Strengths:
Proven Track Record: Incorporated in 2021 and quickly grew as a CDMO for Ayurvedic and nutraceutical products (tablets, capsules, powders, oils). By FY25, it had grown its revenue by 209% and its PAT by 218%. It serves more than 20 countries, including the US, Sri Lanka, and Singapore.
Integrated Manufacturing Expertise: 10,763 sq. ft. A GMP/WHO-GMP/FSSAI-certified facility in Ahmedabad with 13 AHUs, dedicated processing areas, and in-house R&D that combines traditional Ayurveda with modern nutraceuticals for liver care, joint health, and women's health.
High Profitability Metrics: ROE 81.22%, ROCE 36.98%, PAT margin 16.33%, and EBITDA margin 22.79% (FY25) show that premium herbal formulations and contract manufacturing are very efficient.
Location Strategy: Gujarat's pharma hub has advantages for logistics, access to skilled workers, being close to sources of herbal raw materials, and being able to export goods to the global wellness market.
Risks
Short Operating History: Founded in 2021 (4 years), with a limited track record, this company is at risk of failing to scale its CDMO operations because of competition in the nutraceuticals market.
Revenue Concentration: In the CDMO model, clients and suppliers may depend on each other, and growth depends on new contracts and changes in the international market.
Regulatory Dependencies: Risks of not following FSSAI/GMP rules, changes in the quality of raw materials, and changes in export rules for herbal products.
Margin Pressures: Higher costs for herbal extracts, competition in e-commerce and pharmacy channels, and problems with scaling in the premium segment.
According to the RHP filings, Accretion Nutraveda Ltd has strong financials, with revenue growth of 209% in FY25 and PAT growth of 218%. This is due to the rapid scaling of CDMO for Ayurvedic nutraceuticals, high demand for premium herbal formulations, the growth of e-commerce and pharmacy distribution, and exports to more than 20 countries.
Strategically placed in India's $18–22 billion nutraceuticals market (18–22% CAGR through 2030), driven by a focus on immunity after the pandemic, government Ayurveda schemes (₹10,000+ Cr push), tier-2 wellness penetration, and e-pharmacy growth from 15% to 35% market share, with an ROE of 81.22% and EBITDA margins of 22.79%.
The ₹24.77 Cr BSE SME IPO, which is priced between ₹122 and ₹129, trades at a fair 3.8–4.2 times FY25 sales and 22–25 times EPS (after the issue) compared to nutraceutical companies like Walpar Nutritions (23.94x PE) and Influx Healthcare (25.93x PE).
Investors are advised to exercise discretion and refer to the full DRHP/RHP document before reaching any investment decision. This analysis is solely intended for informative purposes and should not be construed as investment advice.
Action Links:
To apply for Accretion Nutraveda IPO, open a demat account here
Accretion Nutraveda IPO Subscription Status: Check live subscription here
Accretion Nutraveda IPO GMP Update: Check latest grey market premium here
1. What are the key dates for the Accretion Nutraveda IPO?
The Accretion Nutraveda Limited BSE SME IPO opens January 28-30, 2026, with anchor bidding on Jan 26, share allotment on February 2, and listing on BSE SME on February 4, 2026.
Track Accretion Nutraveda IPO subscription status live here from Finnpick.
2. What is the Accretion Nutraveda IPO price band and lot size?
The IPO price band stands at ₹122-129 per share (₹10 face value), with a minimum lot size of 1,000 shares requiring ₹122,000-₹129,000 for retail investors.
3. What is Accretion Nutraveda IPO FY25 Financials ROE PAT?
The financials of Accretion Nutraveda stand at revenue growth of 209% YoY, PAT growth of 218%, ROE of 81.22%, ROCE of 36.98%, EBITDA margin of 22.79%, and PAT margin of 16.33% amid nutraceutical/export expansion.
4. How to apply for the Accretion Nutraveda IPO?
Open a demat here (Zerodha/Upstox/AngelOne) or ASBA by Jan. 30, 4 PM. Monitor the Accretion Nutraveda IPO subscription tracker here.
5. How to check the Accretion Nutraveda IPO allotment status?
The allotment date is on Feb 02 and can be checked on the Kfin Technologies portal RTA portal using PAN/DP ID.
6. What is Accretion Nutraveda IPO GMP today, and what is the subscription status?
The current Grey Market Premium (GMP) stands at ₹0-2 (flat to slight premium) as of Jan 20, indicating a listing around the ₹129-131 range—check daily updates of Accretion Nutraveda IPO GMP trends here and live subscription status here from the Jan 28th opening only on Finnpick.
7. What does Accretion Nutraveda specialise in?
The Accretion Nutraveda specialises in Ayurvedic nutraceuticals manufactured in Ahmedabad, Gujarat, and produces herbal supplements (immunity boosters, joint health, digestive aids, and beauty products) via an FSSAI/GMP-certified facility with 100+ SKUs for D2C, e-commerce, pharmacies, and 20+ countries.
8. When is the Accretion Nutraveda IPO listing date?
The Accretion Nutraveda Ltd IPO lists on February 04, 2026, on BSE SME (~T+2 post-allotment Feb 02nd).
9. How is the investor quota allocated in the Accretion Nutraveda IPO?
The investor quota allocated in the Accretion Nutraveda IPO is Retail (RII) 45.99% (8.83 lakh shares), NII/HNI 29.07% (5.58 lakh), QIB (incl. anchors) 19.90% (3.82 lakh), and Market Maker 5.04% (96,800 shares)—a retail-heavy allocation.
